stockrowGinkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.2 million, down 25.1% from fiscal 2024.
- Revenue
- −59.4%
- EPS
- +31.8%
- Free cash flow
- −16.4%
Quarter to June 2026, against a year earlier
Follow DNA
Alert me
Ginkgo Bioworks Holdings, Inc. (DNA) EV/Sales
As of 6 November 2026, Ginkgo Bioworks Holdings, Inc. (DNA) trades at a EV/Sales of 4.0×. Over the past ten years it has ranged from −2.1× (September 2024) to 101× (November 2021); the current reading is higher than 60% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.6× | 1,561.10% |
| FY2024 | 0.0× | (99.63%) |
| FY2023 | 9.4× | 221.34% |
| FY2022 | 2.9× | (90.61%) |
| FY2021 | 31.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 814.87% |
| Mar 2026 | 0.4× | (36.76%) |
| Dec 2025 | 0.6× | (74.56%) |
| Sep 2025 | 2.3× | 157.16% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| DNA Ginkgo Bioworks Holdings, Inc. | 4.0× |
| OABI OmniAb, Inc. compare | 14.5× |
| ACHV Achieve Life Sciences, Inc. compare | 29.0× |
| SLDB Solid Biosciences Inc. compare | 57.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)